Antioxidants preserve vision in retina disease

Article

Consumption of antioxidants may enable retinal degeneration patients to preserve vision even while vascular abnormalities continue to exist, concluded a study published online ahead of print by the Journal of Clinical Investigation.

Consumption of antioxidants may enable retinal degeneration patients to preserve vision even while vascular abnormalities continue to exist, concluded a study published online ahead of print by the Journal of Clinical Investigation.

Professor Martin Friedlander, MD, PhD of Scripps Research Institute, US and colleagues examined mice with dysfunctional VLDL receptors, which imitate abnormal retinal neovascularisation associated with death of the photoreceptor cells in humans. Such symptoms are associated with conditions such as retinal angiomatous proliferation (RAP) and macular telangiectasia (MacTel).

The team found that abnormalities of the intraretinal vasculature and associated neuronal cell death were correlated with increased oxidative stress markers; there oxidative stress markers were mediated either by nutritional antioxidant supplements or by targeted topical antioxidant delivery, although the presence of antioxidants had no impact on the existing vascular abnormalities.

Therefore the researchers concluded that, by reducing oxidative stress, photoreceptor cells could be preserved and functional vision maintained by RAP and MacTel patients even while retinal vasculature is not improved.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.